The first large-scale data on the effects of SGLT-2 inhibition on diabetic kidney disease progression will be provided by the Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants with Diabetic Nephropathy (CREDENCE) [74], which has recently been stopped early for benefit at the formal interim analysis planned for once 405 participants had experienced a primary outcome [75, 76]. This evidence concerns the gene SLC5A2 and diabetic kidney disease.